Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Business Wire

03-04

SAN DIEGO, March 03, 2025--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11^th at 3:00 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and depression. For more information, please visit www.contineum-tx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250303275278/en/

Contacts

Steve Kunszabo
Contineum Therapeutics
Senior Director, Investor Relations & Corporate Communications
858-649-1158
skunszabo@contineum-tx.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2516561666"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516561666\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2516561666?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-04 05:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2516561666","market":"us","top_or_hot":-1,"title":"Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"663\" src=\"https://s1.yimg.com/uu/api/res/1.2/oc.1wU3pe0YWi23kx9SQ3w--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/0b8ae5bf6f7273cffae59afa381b1265\" title=\"\" width=\"1875\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>SAN DIEGO, March 03, 2025</b>--(BUSINESS WIRE)--Contineum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11<sup>th</sup> at 3:00 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.</p>\n<p><b>About Contineum Therapeutics</b></p>\n<p>Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&amp;I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and depression. For more information, please visit www.contineum-tx.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250303275278/en/</span></p>\n<p><b>Contacts</b></p>\n<p>Steve Kunszabo<br/>Contineum Therapeutics<br/>Senior Director, Investor Relations &amp; Corporate Communications<br/>858-649-1158<br/>skunszabo@contineum-tx.com<br/><br/><br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nContineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Business Wire</strong><span class=\"h-time small\">2025-03-04 05:05</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body>\n<figure>\n<img border=\"0\" height=\"663\" src=\"https://s1.yimg.com/uu/api/res/1.2/oc.1wU3pe0YWi23kx9SQ3w--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/0b8ae5bf6f7273cffae59afa381b1265\" title=\"\" width=\"1875\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>SAN DIEGO, March 03, 2025</b>--(BUSINESS WIRE)--Contineum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11<sup>th</sup> at 3:00 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.</p>\n<p><b>About Contineum Therapeutics</b></p>\n<p>Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&amp;I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and depression. For more information, please visit www.contineum-tx.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250303275278/en/</span></p>\n<p><b>Contacts</b></p>\n<p>Steve Kunszabo<br/>Contineum Therapeutics<br/>Senior Director, Investor Relations &amp; Corporate Communications<br/>858-649-1158<br/>skunszabo@contineum-tx.com<br/><br/><br/><br/></p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/contineum-therapeutics-present-2025-leerink-210500502.html\">Business Wire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4137","symbol_name":"綜合支持服務","start_time":0,"source_url":"https://finance.yahoo.com/news/contineum-therapeutics-present-2025-leerink-210500502.html","article_id":"2516561666","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516561666","pubTimestamp":1741035900,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"SAN DIEGO, March 03, 2025----Contineum Therapeutics, Inc.  , a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology  indications, today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 3:00 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.Contineum Therapeutics  is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 re","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4137":"综合支持服务","BK4139":"生物科技","BK4007":"制药","CTNM":"Contineum Therapeutics, INC.","LENZ":"Therapeutics","HCSG":"医疗保健服务"},"translate_title":"Contineum Therapeutics将出席2025年Leerink Partners全球医疗保健会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTNM":1,"HCSG":1,"LENZ":1},"content_text":"SAN DIEGO, March 03, 2025--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 3:00 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.\nAbout Contineum Therapeutics\nContineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and depression. For more information, please visit www.contineum-tx.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250303275278/en/\nContacts\nSteve KunszaboContineum TherapeuticsSenior Director, Investor Relations & Corporate Communications858-649-1158skunszabo@contineum-tx.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}